Vertex Ventures HC, a leading women-led global healthcare investment firm, has announced the launch of its third fund, Fund III, with a total capital of $200 million. The firm aims to support and empower groundbreaking life sciences and medical technology companies that are driving innovation and seeking to improve patient outcomes.
With technology rapidly reshaping industries and scientific advancements pushing boundaries, Vertex Ventures HC recognizes the immense potential of companies dedicated to transforming healthcare and making a lasting impact on society.
As one of the few women-led funds in the healthcare sector, Vertex Ventures HC takes pride in its track record of success in nurturing visionary entrepreneurs from the inception of their companies to successful exits.
Leadership and Expertise
Vertex Ventures HC is guided by a science-first, diversified investment strategy and is spearheaded by Managing Directors Lori Hu and Christine Brennan.
Together, they bring deep expertise in both investing and operations, having led numerous investments resulting in successful exits through mergers and acquisitions (M&A) or initial public offerings (IPO).
The firm places a strong emphasis on long-term growth and actively promotes diversity at the board and executive levels while nurturing teams for sustainable success.
Fund III will primarily focus on early-stage companies demonstrating disruptive technologies, breakthrough research, and a clear pathway toward developing new medicines.
With its extensive network of industry experts, entrepreneurs, and researchers, Vertex Ventures HC aims to provide portfolio companies with access to vital resources, strategic partnerships, and mentorship opportunities.
Expanding Impact and International Reach
Since its establishment in 2014, the venture firm has managed assets totaling $550 million and invested in over 25 portfolio companies dedicated to bringing transformative therapies, healthcare innovation and new technologies to patients.
Notably, the firm has seen success with nearly 20 clinical-stage assets and three products cleared by the US Food and Drug Administration (FDA).
With strong international investment networks and links to Asia, Vertex Ventures HC offers unique advantages to its portfolio companies, including connections for business development, manufacturing, clinical collaboration, and fundraising opportunities.
Vertex Ventures HC’s commitment to advancing healthcare innovation and driving positive change extends beyond investment. The firm actively works to improve diversity at the board and executive levels within the companies it supports, recognizing the importance of diverse perspectives and experiences in fostering innovation and driving meaningful outcomes.
A Promising Future
With the launch of Fund III, the venture firm is well-positioned to fuel healthcare innovation, growth and advancement of medicines by providing capital, strategic guidance, and invaluable expertise to emerging companies developing cutting-edge solutions.
The firm remains dedicated to supporting visionary entrepreneurs throughout market cycles and contributing to the continued transformation of healthcare.
As Vertex Ventures HC’s Fund III aims to revolutionize the healthcare industry, the firm’s commitment to empowering innovative companies and improving patient outcomes is set to leave a lasting impact on the global healthcare landscape.
